百济神州美股涨近7%，FDA官网显示，百济神州的泽布替尼片剂获批上市。 ...

以下文章来源于动脉网 ，作者Melody 动脉网 . 动脉网（www.vbdata.cn）聚焦于技术驱动下生命健康领域产业创新和变革的报道与研究。 报告措辞强硬，明确指出："中国在过去20年将生物技术作为国家战略重点，大规模投入资源，使其在多个生物技术核心领域实现显著赶超，并由此 构成对美国主导地位的直接挑战。" 作者 | Melody 来源 | 动脉网 导语： 在美国管控、打压、警告的三重围堵下，中国生物医药却反手主导交易议价，坐上了全球创新药的"卖方席"。 今年4月，美国国家新兴生物技术安全委员会（NSCEB）发布了一份极具分量的报告。 这份题为《Charting the Future of Biotechnology》的报 告，首次从国家安全高度全面审视美国生物技术面临的全球竞争格局，将中国生物医药产业视作最具战略挑战性的对手。 NSCEB援引多项行业数据指出，中国已经通过20年的政策倾斜、产业集群发展与资本驱动，从研发到制造构建起完整的生物科技体系。 一些数据包括： ● 中国生物科技公司市值增长：2016-2021年，中国生物科技企业的市值增长了100倍，达到约3000亿美元，成为全球仅次于美国的生物 ...

Core Viewpoint - The innovation drug sector is a prominent investment theme this year, showing strong performance driven by policy support, global competitiveness, and commercial profitability [1][3][31]. Group 1: Market Performance - The Hang Seng Pharmaceutical ETF (159892) increased by 60% this year, while the STAR Pharmaceutical ETF (588130) rose by 10.9% in the last ten trading days [3][27]. - Despite a recent pullback, the innovation drug sector continues to dominate the ETF performance rankings [2][3]. Group 2: Driving Factors - Two main reasons for the strong performance of innovation drugs: improvement in the macroeconomic environment and favorable policy developments [4][5]. - The U.S. CPI in May was lower than expected, leading to increased market expectations for a potential interest rate cut by the Federal Reserve, which would benefit the valuation of innovation drug stocks [4]. Group 3: Market Dynamics - The innovation drug sector is experiencing a turning point characterized by macroeconomic recovery, industry fundamentals, and valuation adjustments [9][10]. - The latest PE ratio of the Hang Seng Biotechnology Index is 27.64, indicating room for further valuation recovery as it remains below the historical range of the past decade [11]. Group 4: Industry Developments - Recent approvals of 11 innovative drugs by the National Medical Products Administration signify a growing pipeline for domestic innovation drug companies [11][12]. - Successful international collaborations and participation in global events like the ASCO conference highlight the competitive strength of Chinese innovation drug firms [11][12]. Group 5: Liquidity and Investment Trends - The influx of foreign capital into the Hong Kong market is evident, with 27 companies listed this year, 15 of which attracted foreign cornerstone investors [19][20]. - The average daily trading volume in Hong Kong has significantly increased, reflecting heightened liquidity that benefits the innovation drug sector [25][27]. Group 6: Future Outlook - The innovation drug sector is expected to continue benefiting from a favorable macroeconomic environment, policy support, and increasing global competitiveness [31][34]. - The current growth cycle for innovation drugs is distinct due to the backdrop of macroeconomic recovery and industry value reassessment [33][34].

Core Viewpoint - The innovative drug sector is a significant investment theme this year, showing strong performance and potential for continued growth driven by macroeconomic improvements, supportive policies, and the realization of commercial profits [1][3][33]. Group 1: Market Performance - The Hang Seng Pharmaceutical ETF (159892) has risen by approximately 60% this year, indicating a strong recovery in the pharmaceutical sector after four years of downturn [3]. - Despite a recent pullback, the innovative drug sector continues to dominate the ETF performance rankings, with the Hang Seng Pharmaceutical ETF increasing by 4.18% and the Sci-Tech Pharmaceutical ETF (588130) by 2.21% [2][3]. Group 2: Drivers of Strength - Two main reasons for the strength of innovative drugs are the improving macroeconomic environment and favorable policy developments [4][5]. - The U.S. CPI in May was lower than expected, leading to increased market expectations for a potential 100 basis point rate cut by the Federal Reserve, which would benefit the valuation of innovative drug stocks [4]. - Recent policy initiatives, such as the improvement of basic medical insurance drug lists and the establishment of bio-manufacturing platforms, further support the innovative drug sector [5]. Group 3: Market Dynamics - The innovative drug sector has outperformed many other popular sectors over the past six months, indicating a shift in market sentiment [6]. - The concept of "turning points" is crucial, encompassing macroeconomic, industry, and company fundamentals, as well as valuation aspects [9][10]. - The current PE ratio of the Hang Seng Biotechnology Index is 27.64, suggesting that there is still room for valuation recovery as it remains below 90% of the historical range over the past decade [11]. Group 4: Growth Opportunities - The approval of multiple innovative drugs by the National Medical Products Administration, including 11 new drugs on May 29, highlights the growing pipeline and market potential for innovative drug companies [11][12]. - Successful international collaborations and the recognition of domestic innovative drugs at global events like the ASCO conference demonstrate the competitive strength of Chinese pharmaceutical companies [11][12]. Group 5: Liquidity and Investment Trends - The influx of foreign capital into the Hong Kong market, with 27 IPOs and 15 involving foreign cornerstone investors this year, indicates a reversal in sentiment towards Hong Kong stocks [19][20]. - The average daily trading volume in Hong Kong has significantly increased, reflecting heightened liquidity that benefits the innovative drug sector [25][27]. - Morgan Stanley projects continued high trading activity in Hong Kong, driven by increased A+H listings and potential capital inflows due to favorable monetary conditions [28]. Group 6: Future Outlook - The innovative drug sector is positioned for sustained growth, supported by a combination of policy, profitability, and internationalization [33]. - The current growth cycle is distinct due to the macroeconomic recovery, industry revaluation, and increased liquidity, leading to stronger-than-expected performance [35][36]. - However, not all companies will benefit equally, and only those with clinical value and commercialization capabilities are likely to thrive in the long term [37].

A股创新药概念持续活跃，海思科尾盘涨停，奥赛康此前涨停，舒泰神、睿智医药涨超10%，千红制 药、百济神州、长春高新涨超5%。 ...

智通财经6月12日电，午后创新药概念再度拉升，百济神州涨超7%，再创历史新高，此前奥赛康涨停， 荣昌生物、睿智医药、博瑞医药涨超10%，海思科、舒泰神、万邦德等多股涨超5%。消息面上，今日 智通财经记者获悉，港股创新药企中国生物制药在第46届高盛全球医疗健康年会上透露，今年将至少有 1个重量级的out-license交易落地。该股受此消息刺激大涨超15%，总市值突破1000亿港元。 创新药概念再度拉升 百济神州涨超7%创历史新高 ...

截至2025年6月12日 11:09，恒生医疗保健指数强势上涨3.52%，成分股中国生物制药上涨15.09%，美中嘉和上涨10.86%，绿叶制药上涨10.32%，再鼎医药、 博安生物等个股跟涨。恒生医疗指数ETF(159557)上涨3.10%。拉长时间看，截至2025年6月11日，恒生医疗指数ETF近1周累计上涨6.85%，涨幅排名可比基 金第一。 | 涨幅 | 成交额 | 近1月 涨幅 | | --- | --- | --- | | 超3.1% | 超3000万 | 可比基金 | | | | 第 | | 近2周 新增规模 | 近1年超越基准 年化收益 | 持有1年 盈利概率 | | 可比基金 | 1.33% | 100.00% | | 第 | | | | 费率 | 跟踪指数估值 | 关联基金 | | 可比基金 | 近3年 | 018432(A类) | | 最低 | 低位 | 018433(C类) workers (2001) 1 - groups and and and and and the may be and the may be the may be the may be the | 近期，多款创新 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期： 2025年6月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 (2)第一章節/1/A/1部所列股份并非来自本公司股權計劃授权的股份池。請參考後續證券變動月報表，以了解股權计划股份池中未来可发行的股份剩余数量。 (3)第一章節/1/A部所述開始及結束日期的結存数量不包括向公司的託管公司發行的普通股，該等股份用以換取相應數量的美國存託股份,旨在確保其託管公司可隨時動用 美國存託股份用於滿足受限制股份單位的歸屬及不時行使任何期權。详情請參考後續證券變動月報表。 (4)第一章節/1/A部所述開始及結束日期的結存数量包括2025年5月21日向本公司全資子公司BG NC 2, Lt ...

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

Summary of Conference Call Notes Industry Overview - The conference focuses on the innovative pharmaceutical sector, particularly the PD-(L)1 Plus treatment landscape, which is becoming a competitive area for overseas pharmaceutical companies [1][2]. Key Insights and Arguments - **Market Performance**: The pharmaceutical sector has shown strong performance recently, with significant volatility in innovative drugs. The core stocks have remained relatively stable during adjustments, driven by short-term trading dynamics [3]. - **Investment Outlook**: There is a strong bullish sentiment towards the innovative drug market, supported by solid underlying logic and clear industry trends. Key innovative drug targets, especially those with BD expectations or PD-1 Plus logic, are expected to perform well even during market corrections [3]. - **Investment Strategy**: Four main investment lines are recommended: Chinese supermarkets, generic drug opportunities, re-evaluation of small-cap pipelines, and large overseas pharmaceuticals. The strategy includes a combination of buying and random rotation for explosive growth [3]. - **Focus Areas**: Attention is drawn to the PD-1 Plus logic, particularly the potential upgrade from PD-1/VEGF to PD-1/IL-2. Upcoming opportunities related to the ADA conference in late June and advancements in medical technology (brain-computer interfaces, rehabilitation robots, AI in healthcare) are highlighted [3]. - **2025 Outlook**: Optimism prevails for the pharmaceutical sector, with expectations of a structural bull market. Focus areas include innovative drugs, new technologies, and industry restructuring [3]. Clinical Data Insights - **Sinda's PD-1/IL-2 (IBI363) Data**: - In non-small cell lung cancer (wild-type), the 1-1.5 mg/kg group showed an ORR of 25.9% and a median OS of 15.3 months, while the 3 mg/kg group had an ORR of 36.7% and a median PFS of 9.3 months, suggesting a potential median OS of 20-25+ months [3]. - In lung adenocarcinoma (wild-type), the low-dose group (0.6/1.5 mg/kg) had an ORR of 13.08% and a median PFS of 2.7 months, while the high-dose group (3 mg/kg) showed an ORR of 24% and a median PFS of 5.6 months, with a potential median OS of 25-30 months [3]. - The data indicates a high OS/PFS ratio, particularly in lung adenocarcinoma, which is rare and suggests a potential to limit metastatic tumors [3][4]. Competitive Landscape - **PD-1 Plus Market**: The PD-(L)1 market is substantial, estimated at around $40 billion, and is undergoing innovation. Major multinational corporations are actively investing in PD-1 Plus, contributing to rising upfront payments in business development [6]. - **Key Companies to Watch**: Notable companies in the PD-1 Plus space include Sinda, Hengrui, BeiGene, Kangfang Biotech, Rongchang Biotech, Aosaikang, and Zhimeng Junshi [6]. Sector-Specific Updates - **Innovative Drugs**: The index for innovative drugs rose by 0.34% last week, with a positive long-term outlook driven by clinical data and business development catalysts [6]. - **Generic Drugs**: The index increased by 1.69%, outperforming the pharmaceutical index. Key events include the approval of a compound release tablet by Shenda and the acceptance of a conditional listing application for a hemophilia drug [6]. - **Traditional Chinese Medicine & Pharmacies**: The Chinese medicine index rose by 0.39%, while pharmacies increased by 1.67%, with a focus on policy impacts and operational strategies [6]. - **Medical Devices**: The medical device index rose by 1.11%, with attention on equipment updates and market recovery [6]. - **Life Sciences**: The life sciences sector saw an average increase of 1.47%, with a focus on operational recovery and investment trends [6]. Additional Considerations - **Stock Selection**: Emphasis on companies with clean shareholding structures, low stock prices, and positive future operational trends. Monitoring monthly operational data and overall consumption data is crucial [7].